hydromorphone

Summary

Summary: An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.

Top Publications

  1. ncbi Opioid equianalgesic conversion: the right dose
    J M Brant
    Saint Vincent Healthcare, Billings, MT, USA
    Clin J Oncol Nurs 5:163-5. 2001
  2. ncbi Safety and efficacy of hydromorphone as an analgesic alternative to morphine in acute pain: a randomized clinical trial
    Andrew K Chang
    Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10467, USA
    Ann Emerg Med 48:164-72. 2006
  3. ncbi Simultaneous determination of codeine, morphine, hydrocodone, hydromorphone, oxycodone, and 6-acetylmorphine in urine, serum, plasma, whole blood, and meconium by LC-MS-MS
    Rebecka Coles
    ARUP Institute for Clinical and Experimental Pathology, ARUP Laboratories Inc, Salt Lake City, Utah 84108, USA
    J Anal Toxicol 31:1-14. 2007
  4. ncbi Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study
    Katri Elina Clemens
    Department of Science and Research, Centre for Palliative Medicine, University of Bonn, Germany
    Jpn J Clin Oncol 37:302-9. 2007
  5. pmc The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers
    Sharon L Walsh
    Department of Behavioral Sciences, Center on Drug and Alcohol Research, University of Kentucky, 515 Oldham Court, Lexington, KY 40502, USA
    Drug Alcohol Depend 98:191-202. 2008
  6. ncbi Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans
    S L Walsh
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 157:151-62. 2001
  7. ncbi Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain
    M Hale
    Gold Coast Research, LLC, Weston, FL 33331, USA
    Curr Med Res Opin 26:1505-18. 2010
  8. ncbi Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study
    Eugenia Oviedo-Joekes
    School of Population and Public Health, University of British Columbia, BC, Canada
    J Subst Abuse Treat 38:408-11. 2010
  9. ncbi Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial
    Andrew K Chang
    Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York 10467, USA
    Am J Geriatr Pharmacother 7:1-10. 2009
  10. ncbi Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs
    A G P Guedes
    Department of Veterinary Small Animal Clinical Sciences, College of Veterinary Medicine, Texas A and M University, College Station, TX 77843 4474, USA
    J Vet Pharmacol Ther 31:334-43. 2008

Detail Information

Publications197 found, 100 shown here

  1. ncbi Opioid equianalgesic conversion: the right dose
    J M Brant
    Saint Vincent Healthcare, Billings, MT, USA
    Clin J Oncol Nurs 5:163-5. 2001
    ..Nurses also play a role in recommending the change and ensuring that patients receive the correct dose...
  2. ncbi Safety and efficacy of hydromorphone as an analgesic alternative to morphine in acute pain: a randomized clinical trial
    Andrew K Chang
    Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10467, USA
    Ann Emerg Med 48:164-72. 2006
    We compare a standard weight-based dose of intravenous hydromorphone (Dilaudid) to a standard weight-based dose of intravenous morphine in adults presenting to the ED with acute severe pain.
  3. ncbi Simultaneous determination of codeine, morphine, hydrocodone, hydromorphone, oxycodone, and 6-acetylmorphine in urine, serum, plasma, whole blood, and meconium by LC-MS-MS
    Rebecka Coles
    ARUP Institute for Clinical and Experimental Pathology, ARUP Laboratories Inc, Salt Lake City, Utah 84108, USA
    J Anal Toxicol 31:1-14. 2007
    ..The six opiates included are codeine, morphine, hydrocodone, hydromorphone, oxycodone, and 6-acetylmorphine (6-AM)...
  4. ncbi Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study
    Katri Elina Clemens
    Department of Science and Research, Centre for Palliative Medicine, University of Bonn, Germany
    Jpn J Clin Oncol 37:302-9. 2007
    ..We thus retrospectively examined the pain management and need for opioid switching in cancer patients admitted to our palliative care unit...
  5. pmc The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers
    Sharon L Walsh
    Department of Behavioral Sciences, Center on Drug and Alcohol Research, University of Kentucky, 515 Oldham Court, Lexington, KY 40502, USA
    Drug Alcohol Depend 98:191-202. 2008
    ..the relative abuse potential and potency of oral oxycodone (10, 20 and 40 mg), hydrocodone (15, 30 and 45 mg), hydromorphone (10, 17.5 and 25mg) and placebo...
  6. ncbi Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans
    S L Walsh
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 157:151-62. 2001
    ....
  7. ncbi Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain
    M Hale
    Gold Coast Research, LLC, Weston, FL 33331, USA
    Curr Med Res Opin 26:1505-18. 2010
    ..placebo-controlled study using a randomized withdrawal design evaluated the efficacy and safety of once-daily OROS hydromorphone ER in the treatment of opioid-tolerant patients with chronic moderate-to-severe low back pain (LBP).
  8. ncbi Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study
    Eugenia Oviedo-Joekes
    School of Population and Public Health, University of British Columbia, BC, Canada
    J Subst Abuse Treat 38:408-11. 2010
    ..randomized and parallel arm trial, this pilot study is aimed at testing if treatment response with injectable hydromorphone differs compared to diacetylmorphine in the treatment of long-term opioid addiction...
  9. ncbi Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial
    Andrew K Chang
    Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York 10467, USA
    Am J Geriatr Pharmacother 7:1-10. 2009
    ..Over the past 10 years, there has been an 11% increase in the number of emergency department (ED) visits by older adults, and pain is their most common chief complaint...
  10. ncbi Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs
    A G P Guedes
    Department of Veterinary Small Animal Clinical Sciences, College of Veterinary Medicine, Texas A and M University, College Station, TX 77843 4474, USA
    J Vet Pharmacol Ther 31:334-43. 2008
    This study evaluated the pharmacokinetics, the sedative and anti-nociceptive effects of intravenous hydromorphone in dogs. Five adult dogs were administered hydromorphone (0.1 mg/kg and 0.2 mg/kg) and morphine (0...
  11. ncbi Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis
    Richard Rauck
    Anesthesiology Pain Management, The Carolinas Pain Institute, Winston Salem, NC 27103, USA
    Pain Pract 13:18-29. 2013
    ..The objective of this study was to evaluate the efficacy and safety of OROS hydromorphone extended-release (ER) compared with placebo in patients with moderate to severe pain associated with OA.
  12. ncbi The pharmacokinetics of a long-acting OROS hydromorphone formulation
    J Turgeon
    Centre Hospitalier de l Universite de Montreal, Hotel Dieu, Masson Pavilion, 3850 Saint Urbain Street, Room 8 109, Montreal, Quebec H2W 1T7, Canada
    Expert Opin Drug Deliv 7:137-44. 2010
    ..New formulations of opiods can provide round-the-clock pain relief to improve pain management and quality of life for patients with chronic pain...
  13. ncbi Two milligrams i.v. hydromorphone is efficacious for treating pain but is associated with oxygen desaturation
    Andrew K Chang
    Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA
    J Opioid Manag 5:75-80. 2009
    To evaluate the safety and efficacy of a single dose of 2 mg i.v. hydromorphone administered to emergency department patients in acute severe pain.
  14. ncbi Steady-state pharmacokinetics of extended-release hydromorphone (OROS hydromorphone): a randomized study in healthy volunteers
    Kenneth Todd Moore
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey, USA
    J Opioid Manag 6:351-8. 2010
    The steady-state pharmacokinetics of an extended-release formulation of hydromorphone, OROS hydromorphone, was investigated in a randomized, open-label, crossover study in healthy volunteers...
  15. ncbi Comparison of plasma histamine levels after intravenous administration of hydromorphone and morphine in dogs
    A G P Guedes
    Department of Veterinary Small Animal Clinical Sciences, College of Veterinary Medicine, Texas A and M University, College Station, TX 77843 4474, USA
    J Vet Pharmacol Ther 30:516-22. 2007
    ..histamine concentrations, behavioral and cardiovascular parameters following intravenous administration of hydromorphone and morphine in conscious dogs...
  16. ncbi Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain
    M Wallace
    San Diego Medical Center, University of California, La Jolla, California, USA
    J Int Med Res 36:343-52. 2008
    This open-label, multicenter study assessed the efficacy and tolerability of conversion to once-daily OROS hydromorphone from previous opioid agonist therapy in patients with chronic cancer pain...
  17. ncbi Opioid switch in palliative care, opioid choice by clinical need and opioid availability
    H C Müller-Busch
    PalliativZentrum Berlin Brandenburg, D 10557 Berlin, Germany
    Eur J Pain 9:571-9. 2005
    ..Recommendation of first line therapy and availability of opioid formulations define the frequency of opioid use. This impedes evaluation of specific differences between the opioids...
  18. ncbi Open-label study on the long-term efficacy, safety, and impact on quality of life of OROS hydromorphone ER in patients with chronic low back pain
    Mark Wallace
    Center for Pain Medicine, Department of Anesthesiology, University of California, San Diego School of Medicine, La Jolla, California 92037 7650, USA
    Pain Med 11:1477-88. 2010
    To investigate the efficacy, safety, and impact on quality of life of long-term administration of OROS hydromorphone ER (8-128mg) in patients with chronic low back pain.
  19. ncbi OROS® hydromorphone in chronic pain management: when drug delivery technology matches clinical needs
    F Coluzzi
    Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, I C O T, Latina, Italy
    Minerva Anestesiol 76:1072-84. 2010
    ..In addition, once-daily formulations ensure better patient compliance to prescribed therapies. Hydromorphone was the first opioid to be formulated as a once-daily preparation using OROS® technology...
  20. ncbi A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain
    Heinrich Binsfeld
    Schmerz Zentrum am St Franziskus Hospital Ahlen, Ahlen, Germany
    Pain Pract 10:404-15. 2010
    ..comparative, parallel group study designed to demonstrate the noninferiority of once-daily OROS(®) hydromorphone compared with twice-daily sustained-release (SR) oxycodone in subjects with chronic noncancer pain severe ..
  21. ncbi The effects of fentanyl-like opioids and hydromorphone on human 5-HT3A receptors
    Maria Wittmann
    Klinik und Poliklinik für Anästhesiologie und operative Intensivmedizin, Universitatskliniken Bonn, Bonn, Germany
    Anesth Analg 107:107-12. 2008
    ..Therefore, another morphine (phenanthrene-type) derivative, hydromorphone, and fentanyl including its (4-anilinopiperidine-type) derivatives were tested.
  22. ncbi Comparative clinical effects of hydromorphone and morphine: a meta-analysis
    L Felden
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Br J Anaesth 107:319-28. 2011
    We have conducted a meta-analysis of the clinical effects of morphine and hydromorphone to compare their benefit in analgesia...
  23. ncbi Hydromorphone in the management of cancer-related pain: an update on routes of administration and dosage forms
    Maansi G Kumar
    College of Pharmacy and Allied Health Professions, St John s University, Jamaica, New York, USA
    J Pharm Pharm Sci 10:504-18. 2007
    ..However, recently focus has shifted to the use of hydromorphone, a semi-synthetic derivative of morphine, which is more potent, more soluble and has a comparable side-effect ..
  24. ncbi A systematic review of hydromorphone in acute and chronic pain
    Columba Quigley
    Cancer Center, Hammersmith Hospital, London, United Kingdom
    J Pain Symptom Manage 25:169-78. 2003
    ..For these patients, alternatives such as hydromorphone are recommended. This review explores the evidence for the efficacy of hydromorphone in the management of pain...
  25. ncbi Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine
    Stefan Wirz
    Clinic for Anesthesiology and Intensive Care Medicine, Pain Clinic, University of Bonn, Sigmund Freud Strasse 25, D 53105 Bonn, Germany
    Eur J Pain 13:737-43. 2009
    The purpose of this trial was to evaluate the effect of long-term treatment with oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine on nausea, emesis and constipation.
  26. ncbi Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites
    M T Smith
    School of Pharmacy, University of Queensland, St Lucia, Australia
    Clin Exp Pharmacol Physiol 27:524-8. 2000
    ..myoclonus, seizures) in patients administered large doses of systemic morphine or its structural analogue, hydromorphone (HMOR), has also increased. 4...
  27. ncbi Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, met
    Joseph Pergolizzi
    Johns Hopkins University, Baltimore, Maryland, USA
    Pain Pract 8:287-313. 2008
    ..Slow dose titration helps to reduce the incidence of typical initial adverse events such as nausea and vomiting. Sustained release preparations, including transdermal formulations, increase patient compliance...
  28. ncbi Hydromorphone for acute and chronic pain
    C Quigley
    Medical Oncology, Hammersmith Hospitals Trust, Du Cane Road, London, UK, W12 0NN
    Cochrane Database Syst Rev . 2002
    ..For these patients alternatives such as hydromorphone are recommended...
  29. ncbi Pharmacodynamics of orally administered sustained- release hydromorphone in humans
    M S Angst
    Department of Anesthesia, Stanford University School of Medicine, California 94305 5117, USA
    Anesthesiology 94:63-73. 2001
    The disposition kinetics of hydromorphone generally necessitates oral administration every 4 h of the conventional immediate-release tablet to provide sustained pain relief...
  30. ncbi Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine
    M A Lee
    Department of Palliative Medicine, Roxburghe House, Milltimber, Aberdeen AB13 0HR, UK
    Palliat Med 15:26-34. 2001
    An uncontrolled retrospective study was conducted looking at the use of oral controlled-release hydromorphone in palliative care patients...
  31. pmc Morphine and alternative opioids in cancer pain: the EAPC recommendations
    G W Hanks
    Palliative Medicine, University of Bristol, Bristol Haematology and Oncology Centre, UK
    Br J Cancer 84:587-93. 2001
    ..Practical strategies for dealing with difficult situations are described presenting a consensus view where supporting evidence is lacking. The strength of the evidence on which each recommendation is based is indicated...
  32. ncbi Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain
    Natalie Moryl
    Pain and Palliative Care Service, Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Pain 96:325-8. 2002
    ..A uniformly accepted conversion ratio for substituting methadone with another opioid is currently not available. More data on the rotation from methadone to other opioids are needed...
  33. ncbi Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone
    Megan J Shram
    Clinical Pharmacology Group, Kendle Early Stage, Toronto, Ontario, Canada
    J Clin Psychopharmacol 30:25-33. 2010
    Immediate release (IR) hydromorphone has experienced significant misuse and abuse...
  34. ncbi Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain
    S Wirz
    Clinic for Anesthesiology and Intensive Care Medicine, Pain Clinic Department, University of Bonn, Sigmund Freud Strasse 25, Bonn, Germany
    Support Care Cancer 16:999-1009. 2008
    The purpose of this trial was to evaluate the effect of long-term treatment with either oral sustained-release hydromorphone (HM) or morphine (M) on nausea, emesis, and constipation.
  35. ncbi Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans
    M E Abreu
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224-6823, USA
    Psychopharmacology (Berl) 154:76-84. 2001
    ..speed on the pharmacodynamic responses related to abuse liability and toxicity of intravenous cocaine and hydromorphone. METHODS: Twelve experienced opiate and cocaine users completed this 3-week inpatient study...
  36. ncbi Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain
    Mark Wallace
    San Diego Medical Center, University of California, La Jolla, California, USA
    J Opioid Manag 5:97-105. 2009
    To assess the safety and efficacy of long-term repeated dosing of OROS hydromorphone in chronic pain patients.
  37. ncbi The role of spinal opioid receptors in antinociceptive effects produced by intrathecal administration of hydromorphone and buprenorphine in the rat
    Gopi A Tejwani
    Department of Pharmacology, College of Medicine and Public Health, Ohio State University, 5197 Graves Hall, 333 W 10th Avenue, Columbus, OH 43210 1239, USA
    Anesth Analg 94:1542-6, table of contents. 2002
    ..lack of efficacy or because of the side effects produced by morphine in some patients, other drugs, such as hydromorphone and buprenorphine, should be investigated for their analgesic properties...
  38. ncbi Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone
    Alexandra Ward
    Caro Research Institute, Concord, MA 01742, USA
    Curr Med Res Opin 23:2333-45. 2007
    The Osmotic controlled-Release Oral delivery System (OROS) hydromorphone ensures continuous release of hydromorphone over 24 hours. It is anticipated that this will facilitate optimal pain relief, improve quality of sleep and compliance...
  39. ncbi Hydromorphone: pharmacology and clinical applications in cancer patients
    N Sarhill
    Harry R. Horvitz Center for Palliative Medicine, Taussig Cancer Center of Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Support Care Cancer 9:84-96. 2001
    b>Hydromorphone is a more potent opioid analgesic than morphine and is used for moderate to severe pain. It can be administered by injection, by infusion, by mouth, and rectally. Oral bioavailability is low...
  40. ncbi Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline
    Margaret A Charles
    School of Psychology, Sydney University, Sydney, New South Wales, Australia
    J Pain Symptom Manage 36:29-38. 2008
    ..This pilot, double-blind, controlled, crossover study compared the effects of nebulized hydromorphone, systemic hydromorphone and nebulized saline for the relief of episodic breathlessness in advanced cancer ..
  41. ncbi Managing cancer pain and symptoms of outpatients by rotation to sustained-release hydromorphone: a prospective clinical trial
    Stefan Wirz
    Clinic for Anesthesiology and Intensive Care Medicine, Pain Clinic Department, University of Bonn, Sigmund Freud Str 25, D 53105 Bonn, Germany
    Clin J Pain 22:770-5. 2006
    In this prospective clinical trial we examined the technique of opioid rotation to oral sustained-release hydromorphone for controlling pain and symptoms in outpatients with cancer pain.
  42. ncbi Hydromorphone
    Alison Murray
    Department of Family Medicine, Division of Palliative Medicine, University of Calgary, Calgary, Alberta, Canada
    J Pain Symptom Manage 29:S57-66. 2005
    b>Hydromorphone is a semi-synthetic opioid that has been used widely for acute pain, chronic cancer pain and to a lesser extent, in chronic nonmalignant pain...
  43. ncbi Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials
    Alan B Grosset
    North Idaho Cancer Center, Coeur d Alene, Idaho 83814, USA
    J Pain Symptom Manage 29:584-94. 2005
    ..double-blind, crossover studies with identical designs evaluated the efficacy of oral extended-release hydromorphone (HHER) administered q24h compared with immediate-release hydromorphone (HHIR) dosed four times daily in ..
  44. ncbi Effect of hydromorphone on ventilation in palliative care patients with dyspnea
    Katri Elina Clemens
    Department of Anaesthesiology, Intensive Care Medicine, Palliative Medicine and Pain Therapy, Malteser Hospital Bonn Rhein Sieg, Von Hompesch Strasse 1, Bonn, Germany
    Support Care Cancer 16:93-9. 2008
    This study assessed the effect of hydromorphone treatment on ventilation and the intensity of dyspnea in palliative care patients...
  45. ncbi Clinical pharmacology and pharmacokinetics of once-daily hydromorphone hydrochloride extended-release capsules
    Vijay Vashi
    Purdue Pharma, LP, One Stamford Forum, Stamford, CT 06901 3431, USA
    J Clin Pharmacol 45:547-54. 2005
    b>Hydromorphone hydrochloride extended release (HHER) is a multiparticulate melt-extrusion pellet capsule formulation administered q24h...
  46. ncbi Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide
    A W Wright
    School of Pharmacy, The University of Queensland, Brisbane, Australia
    Life Sci 69:409-20. 2001
    In humans, hydromorphone (HMOR) is metabolised principally by conjugation with glucuronic acid to form hydromorphone-3-glucuronide (H3G), a close structural analogue of morphine-3-glucuronide (M3G), the major metabolite of morphine...
  47. ncbi Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol
    G Sathyan
    ALZA Corporation, 1900 Charleston Road, Mountain View, California 94039, USA
    Curr Med Res Opin 24:297-305. 2008
    The purpose of this study was to investigate the pharmacokinetic properties of a novel, once-daily, controlled-release formulation of hydromorphone (OROS hydromorphone) in the presence of alcohol.
  48. ncbi The side effects of morphine and hydromorphone patient-controlled analgesia
    Daewha Hong
    Department of Anesthesiology, Columbia University Medical Center, 630 West 168th St New York City, NY 10032, USA
    Anesth Analg 107:1384-9. 2008
    Despite "clinical lore" among health care providers that treatment with hydromorphone results in improved pain control and fewer adverse side effects, morphine continues to be the first-line medication for postoperative patient-..
  49. ncbi Antinociceptive effects of hydromorphone, bupivacaine and biphalin released from PLGA polymer after intrathecal implantation in rats
    D Sendil
    Biotechnology Research Unit, Department of Biological Sciences, Middle East Technical University, 06531, Ankara, Turkey
    Biomaterials 24:1969-76. 2003
    ..copolymer poly(L-lactide-co-glycolide) (PLGA) was used to prepare a rod-shaped drug delivery system containing hydromorphone (HM), bupivacaine (BP), both HM and BP, or biphalin (BI)...
  50. pmc Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food
    Gayatri Sathyan
    ALZA Corporation, Mountain View, CA, USA
    BMC Clin Pharmacol 7:2. 2007
    ..study was to compare the pharmacokinetic profile of a novel, once-daily, controlled-release formulation of hydromorphone (OROS hydromorphone) under fasting conditions with that immediately after a high-fat breakfast in healthy ..
  51. ncbi Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain
    Sharon M Weinstein
    MD Anderson Cancer Center, University o f Texas, Houston, Texas, USA
    Clin Ther 28:86-98. 2006
    b>Hydromorphone hydrochloride is a mu-opioid agonist with dose-dependent analgesic properties. Extended-release hydromorphone hydrochloride (ER hydromorphone HCl) capsules have been developed for administration every 24 hours.
  52. ncbi Hydromorphone metabolites: isolation and identification from pooled urine samples of a cancer patient
    M Zheng
    Faculty of Pharmaceutical Sciences, University of British Columbia, 2146 East Mall, Vancouver, BC V6T 1Z3, Canada
    Xenobiotica 32:427-39. 2002
    1. Hydromorphone-3-glucuronide, dihydromorphine, dihydroisomorphine, dihydromorphine-3-glucuronide and dihydroisomorphine-3-glucuronide were isolated from a cancer patient's urine and identified as metabolites of hydromorphone by ..
  53. ncbi A comparison of single-dose caudal clonidine, morphine, or hydromorphone combined with ropivacaine in pediatric patients undergoing ureteral reimplantation
    Thomas R Vetter
    Department of Anesthesia, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Anesth Analg 104:1356-63, table of contents. 2007
    ..We prospectively compared the analgesic, side effect, and rehabilitation profiles of caudal clonidine, hydromorphone, or morphine in a group of 60 pediatric patients undergoing ureteral reimplantation.
  54. ncbi Successful reduction of neuropathic pain associated with spinal cord injury via of a combination of intrathecal hydromorphone and ziconotide: a case report
    M Saulino
    Moss Rehab, Department of Rehabilitation Medicine, Thomas Jefferson University, Elkins Park, PA, USA
    Spinal Cord 45:749-52. 2007
    ..Case report...
  55. ncbi GC-MS quantitation of codeine, morphine, 6-acetylmorphine, hydrocodone, hydromorphone, oxycodone, and oxymorphone in blood
    Robert Meatherall
    Department of Biochemistry, St Boniface General Hospital, Winnipeg, Manitoba, Canada
    J Anal Toxicol 29:301-8. 2005
    ..is described for the simultaneous analysis of seven opiates, codeine, morphine, 6-acetylmorphine, hydrocodone, hydromorphone, oxycodone, and oxymorphone, in blood samples by gas chromatography-mass spectrometry (GC-MS)...
  56. ncbi GC-MS confirmation of codeine, morphine, 6-acetylmorphine, hydrocodone, hydromorphone, oxycodone, and oxymorphone in urine
    R Meatherall
    Department of Biochemistry, St Boniface General Hospital, Winnipeg, Manitoba, Canada
    J Anal Toxicol 23:177-86. 1999
    A procedure for the simultaneous confirmation of codeine, morphine, 6-acetylmorphine, hydrocodone, hydromorphone, oxycodone, and oxymorphone in urine specimens by gas chromatography-mass spectrometry (GC-MS) is described...
  57. ncbi The role of hydromorphone in cancer pain treatment: a systematic review
    Alessandra Pigni
    Fondazione IRCCS Istituto Nazionale Tumori Milano, Italy
    Palliat Med 25:471-7. 2011
    The aim of this systematic review is to evaluate the scientific evidence for the efficacy and side effects of hydromorphone in the management of moderate to severe cancer pain...
  58. ncbi Pharmacokinetics of hydromorphone hydrochloride in healthy dogs
    Butch KuKanich
    PharmCATS and the Department of Anatomy and Physiology, Kansas State University, Manhattan, KS, USA
    Vet Anaesth Analg 35:256-64. 2008
    To assess the pharmacokinetics of hydromorphone administered intravenously (IV) or subcutaneously (SC) to dogs.
  59. ncbi Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis
    Martin Hale
    Gold Coast Research LLC, Weston, FL, USA
    Clin Ther 29:874-88. 2007
    This study compared the efficacy and tolerability of a once-daily controlled-release formulation of hydromorphone (OROS) hydromorphone, Janssen-Cilag, Beerse, Belgium) and twice-daily extended-release (ER) oxycodone in patients with ..
  60. ncbi A randomized study of the effect of oral lamotrigine and hydromorphone on pain and hyperalgesia following heat/capsaicin sensitization
    Karin L Petersen
    Pain Clinical Research Center and Department of Neurology, University of California, San Francisco, CA 94115, USA
    J Pain 4:400-6. 2003
    ..sensitization induced with the heat/capsaicin sensitization model was compared with the effect of oral hydromorphone (8 mg) in healthy volunteers. In a separate session, intravenous remifentanil (0.10 microg.kg(-1)...
  61. ncbi Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain
    Mark Palangio
    Abbott Laboratories, Morris Corporate Center, Parsippany, New Jersey 07054, USA
    J Pain Symptom Manage 23:355-68. 2002
    ..conversion from prior opioid therapy to a novel, once-daily, OROS osmotic technology, extended-release (ER) hydromorphone formulation in an outpatient population with chronic malignant or nonmalignant pain...
  62. ncbi Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers
    David R Drover
    Department of Anesthesia, Stanford University School of Medicine, California 94305 5940, USA
    Anesthesiology 97:827-36. 2002
    To compare the pharmacokinetics of intravenous, oral immediate-release (IR), and oral extended-release (OROS ) formulations of hydromorphone.
  63. ncbi Antinociceptive effects of hydromorphone, butorphanol, or the combination in cats
    B Duncan X Lascelles
    College of Veterinary Medicine, University of Florida, Gainesville, USA
    J Vet Intern Med 18:190-5. 2004
    The goal of this study was to assess the antinociceptive activity of a single dose of hydromorphone or butorphanol and to examine the effect of their coadministration on thermal thresholds in cats...
  64. ncbi A multiple-dose phase I study of intranasal hydromorphone hydrochloride in healthy volunteers
    Anita C Rudy
    Intranasal Technology, Inc, Coldstream Research Campus, 1513 Bull Lea Blvd, Lexington, KY 40511 1200, USA
    Anesth Analg 99:1379-86; table of contents. 2004
    We evaluated the pharmacokinetics, tolerability, and safety of 1 and 2 mg of intranasal hydromorphone hydrochloride in an open-label, single- and multiple-dose study...
  65. ncbi Secondary adrenal failure and secondary amenorrhoea following hydromorphone treatment
    Karsten Müssig
    Clin Endocrinol (Oxf) 66:604-5. 2007
  66. ncbi Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127)
    Mark Wallace
    University of California, San Diego Medical Center, La Jolla, CA, USA
    Curr Med Res Opin 23:981-9. 2007
    To evaluate the safety, tolerability, and efficacy of once-daily osmotic controlled-release oral delivery system (OROS) hydromorphone in patients with chronic low back pain of moderate-to-severe intensity.
  67. pmc Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone
    Gayatri Sathyan
    ALZA Corporation, Mountain View, CA, USA
    BMC Clin Pharmacol 7:3. 2007
    The purpose of this study was investigate the dose proportionality of a novel, once-daily, controlled-release formulation of hydromorphone that utilizes the OROS Push-Pull osmotic pump technology.
  68. pmc Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study
    M Wallace
    San Diego Medical Center, University of California, La Jolla, CA, USA
    Int J Clin Pract 61:1671-6. 2007
    ..The use of opioid analgesics for patients with chronic nonmalignant pain is becoming more widely accepted, and long-acting formulations are an important treatment option...
  69. ncbi [Pain reduced and quality of life improved by sustained-release hydromorphone. Results of an observational study]
    H B Sittig
    Leiter Schmerztherapie Zentrum Unterweser, St Josef Hospital, Bremerhaven
    MMW Fortschr Med 146:95-8. 2004
    A total of 487 patients with severe pain of varying pathogenesis received sustained-release hydromorphone (Palladon) in an observational study...
  70. ncbi Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone
    S A Benetton
    Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada
    Xenobiotica 34:335-44. 2004
    ..to identify the individual human cytochrome P450 (CYP) enzymes responsible for the in vitro N-demethylation of hydromorphone and to determine the potential effect of the inhibition of this metabolic pathway on the formation of other ..
  71. ncbi Equianalgesic dosing of opioids
    Hildegarde J Berdine
    Department of Pharmacy Practice, Duquesne University Mylan School of Pharmacy, Pittsburgh, PA 15282, USA
    J Pain Palliat Care Pharmacother 20:79-84. 2006
    The concept of opioid equianalgesia, limitations in current dose conversion systems, equianalgesic dose tables, and computer assisted dose conversions are discussed. Conversions for methadone, fentanyl and hydromorphone are described.
  72. ncbi Parent/nurse-controlled analgesia for children with developmental delay
    Michelle L Czarnecki
    Jane B Pettit Pain and Palliative Care Center, Children s Hospital of Wisconsin, Milwaukee, WI 53201, USA
    Clin J Pain 24:817-24. 2008
    ..Parent/nurse-controlled analgesia (PNCA) may be an option for these children. However, the safety and efficacy of PNCA have not been thoroughly evaluated and many practitioners are reluctant to use it...
  73. ncbi Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial
    Martin Stockler
    Department of Medicine and School of Public Health, NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia
    J Clin Oncol 22:3389-94. 2004
    ..To determine whether adding regular acetaminophen (paracetamol) could improve pain and well-being in people with advanced cancer and pain despite strong opioids...
  74. ncbi Opioid self-administration in the nerve-injured rat: relevance of antiallodynic effects to drug consumption and effects of intrathecal analgesics
    Thomas J Martin
    Department of Anesthesiology, Wake Forest University School of Medicine, NC 27157, USA
    Anesthesiology 106:312-22. 2007
    ..The authors examined the pharmacology of self-regulated intake of opioids in rats with or without nerve injury and compared the rate of drug intake to reversal of allodynia...
  75. ncbi The metamorphosis of hydromorphone
    Gary M Reisfield
    Division of Palliative Medicine, Department of Community Health and Family Medicine, University of Florida Health Science Center Jacksonville, USA
    J Opioid Manag 1:139-45. 2005
    b>Hydromorphone, one of the oldest and most potent of opioids, is an effective alternative to morphine. With a variety of routes of administration, it has an efficacy similar to that of morphine...
  76. ncbi Femoral nerve block for diaphyseal and distal femoral fractures in the emergency department
    Benedict A Rogers
    J Bone Joint Surg Am 90:1787-8; author reply 1788-9. 2008
  77. ncbi Femoral nerve block for diaphyseal and distal femoral fractures in the emergency department
    Christopher E Mutty
    Department of Orthopaedic Surgery, Wake Forest University Health Sciences, Medical Center Boulevard, Winston Salem, NC 27157, USA
    J Bone Joint Surg Am 89:2599-603. 2007
    ..The purpose of this study was to determine whether a femoral nerve block administered in the emergency department could provide better pain relief for patients with femoral fractures than currently used pain management practices...
  78. doi Equianalgesia: applying evidence-based practice guidelines
    Bruce S Bond
    Our Lady of the Lake Regional Medical Center, Baton Rouge, LA, USA
    Clin J Oncol Nurs 12:527-9. 2008
  79. pmc Multiple opioids in pain management
    Romayne Gallagher
    Division of Palliative Care, University of British Columbia, Vancouver, Canada
    Can Fam Physician 53:2119-20. 2007
  80. ncbi [Pharmacotherapy of chronic, non-tumour related pain. Efficacy, tolerability and patient benefit of an oral osmotic system with hydromorphone]
    Rainer Sabatowski
    UniversitätsSchmerzCentrum, Klinik und Poliklinik für Anästhesiologie, Universitatsklinikum Carl Gustav Carus Dresden
    MMW Fortschr Med 149:119-24. 2007
    An overview of the results of a clinical study is presented in which efficacy, tolerability and patient benefit of a therapy with OROS (ORal OSmotic) hydromorphone (Jurnista) in patients with chronic pain was investigated.
  81. ncbi The management of pain in children with life-limiting illnesses
    Stefan J Friedrichsdorf
    Pain and Palliative Care, Children s Hospitals and Clinics of Minnesota, 2525 Chicago Avenue South, Minneapolis, MN 55404, USA
    Pediatr Clin North Am 54:645-72, x. 2007
    ....
  82. ncbi Pain control via opioid analgesic-local anesthetic loaded IPNs
    Dilek Sendil Keskin
    Middle East Technical University, Department of Biological Sciences, Biotechnology Research Unit, Ankara 06531, Turkey
    Curr Drug Deliv 1:57-64. 2004
    ..study was designed for the construction of a controlled release system for local application of analgesics (hydromorphone (HM), morphine (M), and codeine (C)) and a local anesthetic, bupivacaine (BP)...
  83. doi Spontaneously breathing technique for opioid tolerance
    N Eipe
    Acta Anaesthesiol Scand 52:575-6. 2008
  84. ncbi A randomized double-blind crossover comparison of continuous and intermittent subcutaneous administration of opioid for cancer pain
    Sharon Watanabe
    Department of Symptom Control and Palliative Care, Cross Cancer Institute, Edmonton, Alberta, Canada
    J Palliat Med 11:570-4. 2008
    ..In all cases, patients and investigators expressed no preference for one modality over another. Further research is required to confirm that opioid administration by CSCI and ISCI provide similar analgesic and adverse effects...
  85. ncbi The detection of hydromorphone in urine specimens with high morphine concentrations
    Pamela C McDonough
    Division of Forensic Toxicology, Office of the Armed Forces Medical Examiner, 1413 Research Blvd, Bldg 102, Rockville, MD 20850, USA
    J Forensic Sci 53:752-4. 2008
    A previous study suggested that small amounts of morphine are metabolically converted to hydromorphone. In the present study, morphine positive urine specimens obtained from a postmortem laboratory and a random urinalysis program were ..
  86. ncbi Strategies to induce labor analgesia with epidural hydromorphone
    J M Mhyre
    Int J Obstet Anesth 17:81-2. 2008
  87. ncbi Urine drug test interpretation: what do physicians know?
    Gary M Reisfield
    Department of Community Health and Family Medicine, University of Florida College of Medicine Jacksonville, USA
    J Opioid Manag 3:80-6. 2007
    ..To determine the level of urine drug test (UDT) interpretive knowledge of physicians who use these instruments to monitor adherence in their patients on chronic opioid therapy...
  88. ncbi Stability and compatibility of drug mixtures in an implantable infusion system
    F Bianchi
    Codman Neuro Sciences SA RL, Le Locle, Switzerland
    Anaesthesia 63:972-8. 2008
    ..and the compatibility of mixtures of morphine sulphate, bupivacaine, and clonidine hydrochloride and of hydromorphone, bupivacaine, and clonidine hydrochloride, when used in constant flow implantable pumps under simulated ..
  89. ncbi Correlation between withdrawal symptoms and medication pump residual volume in patients with implantable SynchroMed pumps
    Jamal Taha
    Division of Neurosurgery, Kettering Medical Center, Dayton, Ohio 45429, USA
    Neurosurgery 55:390-3; discussion 393-4. 2004
    ..Minneapolis, MN) develop symptoms of drug withdrawal at residual medication volumes that exceed 2 ml (the alarm residual volume recommended by the manufacturer)...
  90. ncbi The addition of hydromorphone to epidural fentanyl does not affect analgesia in early labour
    Robert K Parker
    Department of Anesthesiology, Baystate Medical Center, Springfield, Massachusetts, USA
    Can J Anaesth 49:600-4. 2002
    ..The current study was designed to determine the influence of hydromorphone added to an epidural fentanyl bolus (e.g., whether there is an increase in duration of analgesia).
  91. ncbi Pain evaluation in patients receiving intravenous patient-controlled analgesia after surgery
    Ghassem E Larijani
    Department of Anesthesiology, Cooper University Hospital, Camden, New Jersey, USA
    Pharmacotherapy 25:1168-73. 2005
    ..To evaluate the effectiveness of intravenous patient-controlled analgesia (PCA) in patients after surgery...
  92. ncbi Opioid rotation in the treatment of joint pain. A review of 67 cases
    R M Grilo
    Rheumatology and Therapeutics Department, CHU Dupuytren, 2 Avenue Martin Luther King, 87042 Limoges, France
    Joint Bone Spine 69:491-4. 2002
    ..To determine that opioid rotation can be useful for establishing a more advantageous analgesia/toxicity relationship in rheumatologic pain...
  93. ncbi The effect of opioids on driving and psychomotor performance in patients with chronic pain
    Michael G Byas-Smith
    Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Clin J Pain 21:345-52. 2005
    ..The hypothesis was that patients with chronic pain on stable opioid analgesic regimens operate their automobiles safely with proficiency equal to normal volunteer controls...
  94. ncbi Use of the infusion pain pump following transverse rectus abdominis muscle flap breast reconstruction
    Albert Losken
    Emory Division of Plastic and Reconstructive Surgery, Paces Plastic Surgery, Atlanta, GA 30308, USA
    Ann Plast Surg 54:479-82. 2005
    ..received patient-controlled analgesia (PCA) (morphine, n = 34; meperidine (Demerol, Sanofi-Synthelabo), n = 1; hydromorphone hydrochloride (Dilaudid, Abbott Pharmaceutical) n = 1)...
  95. ncbi In vivo pain relief effectiveness of an analgesic-anesthetic carrying biodegradable controlled release rod systems
    D Sendil-Keskin
    Middle East Technical University, Department of Biological Sciences and Biotechnology, Biotechnology Research Unit, 06531 Ankara, Turkey
    J Biomater Sci Polym Ed 14:497-514. 2003
    ..We designed a controlled release system of pain relievers, mainly for opioids (morphine, M, codeine, C, and hydromorphone, HM), and a local anesthetic (bupivacaine, BP) in the form of poly(L-lactide-co-glycolide) (PLGA) rods...
  96. ncbi The use of opioids in the postoperative setting: focus on morphine, hydromorphone, and fentanyl
    Julie Golembiewski
    Departmetn of Pharmacy Practice, University of Illinois at Chicago, 60612 7230, USA
    J Perianesth Nurs 20:141-3. 2005
  97. ncbi Antihyperalgesic effect of simultaneously released hydromorphone and bupivacaine from polymer fibers in the rat chronic constriction injury model
    Vasif Hasirci
    Department of Biological Sciences, Biotechnology Research Unit, Middle East Technical University, Ankara, 06531, Turkey
    Life Sci 73:3323-37. 2003
    We aimed to evaluate the antihyperalgesic efficacy of a combination of hydromorphone (HM) and bupivacaine (BP) delivered via controlled release from a biodegradable cylindrical rod...
  98. ncbi Contribution to variability in response to opioids
    Geoffrey W Hanks
    Department of Palliative Medicine, Bristol Haematology and Oncology Centre, University of Bristol, Horfield Road, Bristol, BS2 8ED, UK
    Support Care Cancer 13:145-52. 2005
    ..This article reviews factors that affect the efficacy and tolerability of opioid analgesics and clinical strategies for successful pain mangement...
  99. ncbi The risk of cesarean delivery with neuraxial analgesia given early versus late in labor
    Cynthia A Wong
    Department of Anesthesiology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    N Engl J Med 352:655-65. 2005
    ..0 cm dilated) has been associated with an increased risk of cesarean delivery. It is unclear, however, whether this increase in risk is due to the analgesia or is attributable to other factors...
  100. ncbi Prospective audit of short-term concurrent ketamine, opioid and anti-inflammatory ('triple-agent') therapy for episodes of acute on chronic pain
    P Good
    Department of Medicine, Southern Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University and Medicine Program, Southern Health, McCulloch House, Monash Medical Centre, Melbourne, Victoria, Australia
    Intern Med J 35:39-44. 2005
    ..The clinical hypothesis in this study is that better pain control may be obtained by simultaneous multiple target receptor blockade...
  101. ncbi [Pain reduced and quality of life improved by sustained-release hydromorphone. Results of an observational study]
    H B Sittig
    Schmerztherapie Zentrum, Unterweser, St Josef Hospital, Wienerstrasse 1, D 27568 Bremerhaven
    MMW Fortschr Med 146:45. 2004

Research Grants51

  1. Opioid Antagonist Discrimination: A Model of Withdrawal
    Alison Oliveto; Fiscal Year: 2011
    ..Previously, we showed that the opioid agonist hydromorphone blocks the effects of NX while the partial opioid agonists nalbuphine and butorphanol, and the alpha2-..
  2. Characterization of Toxicity with Spinal Opiates
    Tony L Yaksh; Fiscal Year: 2010
    ..Our studies show that granulomas are induced by morphine, hydromorphone, methadone and DAMGO, but not fentanyl...
  3. Opioid selection and the risk of serious infections in older adults
    Carlos G Grijalva; Fiscal Year: 2013
    ..g. codeine) reduces immunosuppression, and substitution of a carbonyl group at C6 (e.g. hydromorphone) eliminates the immunosuppressive effects...
  4. Optimizing Pain Treatment while Reducing Abuse Liability in Opioid Dependence
    David Andrew Tompkins; Fiscal Year: 2013
    ..pain threshold and tolerance), subjective, and objective drug effects provided by intravenous doses of hydromorphone and buprenorphine in 3 groups: pain-free methadone maintained participants (N=30), pain-free buprenorphine ..
  5. A Delta/Kappa OR Ligand: Taking Advantage of Heteromers to Control Pain
    Boris Tabakoff; Fiscal Year: 2013
    ..These Phase I SBIR studies should set the stage for further development through the SBIR Phase II program and completion of pre-clinical work for a most promising pain medication. ..
  6. Abuse-deterrent sustained-release hydromorphone
    MICHAEL ZAMLOOT; Fiscal Year: 2006
    ..In 2005, Purdue Pharma plans to launch sustained-release hydromorphone, a more potent narcotic than oxycodone...
  7. Rapid Transdermal Delivery of Opioid Pain Medications
    Alan Smith; Fiscal Year: 2002
    ..The opioid candidates to be tested in vitro with the thermal microporation method include morphine, hydromorphone, fentanyl, and alfentanil...
  8. HUMAN POLYDRUG USE: AND ECONOMIC ANALYSIS
    Ralph Spiga; Fiscal Year: 2001
    ..STUDY 2 will examine methadone consumption when vehicle and hydromorphone are the concurrent drug alternatives...
  9. DYNORPHIN A OPIOID PEPTIDE--INTERACTIONS WITH MORPHINE
    BEHZAD KHOSROVI; Fiscal Year: 1993
    ..a pilot study to evaluate the ability of dynorphin A (1- 13) to enhance the analgesic effect of morphine (or hydromorphone) in patients requiring relatively high doses of these opioids...
  10. NARCOTIC DRUG AND OPIOID PEPTIDE BASIC RESEARCH PROJECT
    James Woods; Fiscal Year: 2002
    ..PET imaging studies will compare buprenorphine's binding to central mu-opioid receptors with its antagonism of hydromorphone's pharmacological effects. Two of the areas of study are new...
  11. NARCOTIC DRUG AND OPIOID PEPTIDE BASIC RESEARCH PROJECT
    James Woods; Fiscal Year: 2006
    ..PET imaging studies will compare buprenorphine's binding to central mu-receptors with its antagonism of hydromorphone's pharmacological effects...
  12. Reducing Cocaine/Heroin Abuse with SR-Amphetamine and Buprenorphine
    Mark Greenwald; Fiscal Year: 2009
    ..in weeks 1-3) will: [1a] be safe and well tolerated;[1b] decrease choice of cocaine alone or combined with hydromorphone (HYD), relative to HYD alone and placebo on a choice progressive ratio schedule (4 conditions;randomized ..
  13. Human Laboratory Model of Cocaine Treatment: Behavioral Economic Analysis
    Mark K Greenwald; Fiscal Year: 2010
    ....
  14. SEROTONIN Treatment of Cocaine Dependence
    ERIC STRAIN; Fiscal Year: 2005
    ....
  15. Liposomal Opioids Extend Analgesia in Laboratory Animals
    Lisa Krugner Higby; Fiscal Year: 2008
    ..Novel methods of time-release preparation for potent, pure agonist opioids such as oxymorphone and hydromorphone represent a significant refinement in the way in which these drugs are administered to both rodents and larger ..
  16. Molecular Genetics of Inattention in Australia
    THEODORE CICERO; Fiscal Year: 2009
    ..This will be at a marked cost savings due to the employment of existing well-characterized samples and the long history of collaborative studies between investigators from Australia and the United States. ..
  17. EVALUATION OF OPIOID ANTAGONIST ACTIVITY IN HUMANS
    Eric C Strain; Fiscal Year: 2010
    ....
  18. Hyperalgesia in Methadone Patients: Can it be Treated?
    Margaret Compton; Fiscal Year: 2007
    ..abstract_text> ..
  19. OPIATE ENDOCRINE INTERACTIONS--DEVELOPMENTAL ASPECTS
    THEODORE CICERO; Fiscal Year: 2003
    ..The proposed animal studies could establish whether gender differences exist and if these differences are based on inherent, first-order biological differences between the sexes. ..
  20. Neuropharmacology of Tramadol: Clinical Efficacy and Abuse Potential
    WILLIAM WALTON STOOPS; Fiscal Year: 2010
    ..Developing analgesics with reduced abuse potential may reduce the prevalence of prescription opioid misuse and subsequent opioid use disorders. ..
  21. CLINICAL RESEARCH ON DRUG ABUSE
    ERIC STRAIN; Fiscal Year: 2006
    ..Thus, this ISA represents a good investment by NIDA. ..
  22. Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial
    Sharon Walsh; Fiscal Year: 2008
    ..This study will provide preliminary safety and efficacy data on the potential utility of atomoxetine and determine whether a larger-scale evaluation is warranted. [unreadable] [unreadable] [unreadable]..
  23. GLUTAMATERGIC SYSTEMS IN PAIN AND OPIOID ACTION
    Charles Inturrisi; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  24. Adulterants, drugs, coingestants and associated HIV risk
    Edward Boyer; Fiscal Year: 2008
    ..Integrating analytical laboratory science into social science methods represents an innovative interdisciplinary approach to HIV research that will provide a basis for future research on these substances. ..
  25. Agonist Replacement Therapy for Cocaine Dependence: Identifying Novel Medications
    CRAIG RUSH; Fiscal Year: 2009
    ..Identifying novel agonist replacement therapies is important because clinicians may be reluctant to use d-amphetamine because of its abuse potential. ..
  26. Role of the Amygdala in Opioid Self-administration in Rats with Chronic Pain.
    Thomas Martin; Fiscal Year: 2009
    ....
  27. TMS in the Management of Postoperative Pain
    Jeffrey J Borckardt; Fiscal Year: 2010
    ..Thus, new interventions that have the potential to reduce reliance on postoperative morphine in this patient population such as TMS need to be explored. ..
  28. New Neural Targets for Opioid Use Disorders: Human Studies
    Sharon L Walsh; Fiscal Year: 2010
    ..Thus, these studies, conducted in healthy humans, will provide fundamental information regarding the potential for this system as a target for development of new treatment agents for opioid use disorders. ..
  29. AMINOBENZOMORPHAN: POTENTIAL COCAINE ABUSE MEDICATIONS
    Mark Wentland; Fiscal Year: 2009
    ..Radioligand binding, [35S]GTPvS, and mouse antinociceptive assays will be used to characterize new targets pharmacologically. ..
  30. PHARMACOLOGICAL MODULATION OF COCAINE EFFECTS
    George Bigelow; Fiscal Year: 2002
    ....
  31. Evaluation of Novel Treatments for Stimulant Dependence
    Sharon Walsh; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  32. Factors in Drug Dependence
    Sharon Walsh; Fiscal Year: 2005
    ..abstract_text> ..
  33. AGING AND PERIOPERATIVE OUTCOMES
    JACQUELINE LEUNG; Fiscal Year: 2005
    ..We believe that our studies will provide important results contributing ultimately to the improvement of perioperative outcomes in geriatric patients. ..
  34. PHARMACOLOGY OF COMBINED EPHEDRINE/CAFFEINE SUPPLEMENTS
    Christine Haller; Fiscal Year: 2004
    ..The long-term objective for the proposed studies is to develop Dr. Haller into an independent career clinical researcher in this field of study. ..
  35. ASSESSING ABUSE POTENTIAL IN HUMAN--CNS STIMULANTS
    CRAIG RUSH; Fiscal Year: 2004
    ..abstract_text> ..
  36. Relationship Between the Internet and Illicit Drug Use
    Edward Boyer; Fiscal Year: 2003
    ..After addressing the study hypotheses, we will conduct exploratory analyses to compare respondents who do and do not use the Internet to obtain information on illicit drugs. ..
  37. GABA Agonists as Pharmacotherapies for Cocaine Abuse
    CRAIG RUSH; Fiscal Year: 2003
    ..Finally, the proposed research will allow us to conduct retrospective analyses to determine the influence of individual differences (e.g., gender, other drug use) on the reinforcing and subjective effects of cocaine. ..
  38. THERAPEUTIC POTENTIAL OF KAPPA-OPIOIDS AGAINST COCAINE
    Sharon Walsh; Fiscal Year: 2002
    ..These studies are relevant to the treatment of cocaine abuse and may lead to the development of an effective pharmacotherapy, thereby, reducing the HIV and other health risks associated with cocaine abuse and intravenous drug abuse. ..
  39. HUMAN BEHAVIORAL PHARMACOLOGY OF DRUG ABUSE
    George Bigelow; Fiscal Year: 2002
    ..The cocaine dependence clinical trials will evaluate the efficacy of the serotonergic agents tryptophan and fluoxetine in the context of an incentive-based behavior therapy program. ..
  40. Human Cocaine Discrimination
    CRAIG RUSH; Fiscal Year: 2006
    ..Elucidating the role of dopamine in mediating the effects of cocaine may guide the development of pharmacological interventions for cocaine. ..
  41. Nasal Delivery of Naltrexone for Treatment of Alcoholism
    Daniel Wermeling; Fiscal Year: 2006
    ..The long-term goal of this work is to develop and commercialize nasal delivered NTX for the treatment of alcoholism. [unreadable] [unreadable] [unreadable]..
  42. Sublingual Buprenorphine for Chronic Pain in Patients at Risk for Drug Abuse
    Andrew Rosenblum; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  43. Opioids, internet pharmacies, self-treated chronic pain, and HIV/AIDS
    Edward Boyer; Fiscal Year: 2007
    ..abstract_text> ..
  44. Cost and Adherence in Drug Abuse Treatment
    KENNETH STOLLER; Fiscal Year: 2007
    ..This accomplishment will document my transition to the status of an independent patient-oriented researcher and recognized expert in the field of drug abuse treatment. [unreadable] [unreadable] [unreadable] [unreadable]..
  45. RVM CCK, Pain, and Opioid Tolerance
    Todd Vanderah; Fiscal Year: 2006
    ..These approaches may allow for sustained efficacy of morphine or opioids and their use in the treatment of chronic or prolonged pain states. ..
  46. Glutamate receptors in pain and addictive behaviors
    Charles Inturrisi; Fiscal Year: 2007
    ..This SSA award will also allow me to continue the reduction in teaching and administrative responsibilities that has significantly increased the time I was able to devote to enhancing my scientific skills. ..
  47. Stimulant Abuse Pharmacotherapy: Novel Antipsychotics
    CRAIG RUSH; Fiscal Year: 2009
    ..The proposed research will provide initial scientific and clinical information regarding the use of aripiprazole as a pharmacotherapy for the treatment of methamphetamine dependence, and guide the design of future clinical trials. ..
  48. NOVEL NONPEPTIDE LIGANDS FOR THE OPIOID RECEPTORS
    Subramaniam Ananthan; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  49. Preventing Cocaine Relapse: Developing Pharmacotherapies
    CRAIG RUSH; Fiscal Year: 2008
    ..Reducing relapse to drug use is important because intravenous abuse of cocaine may be associated with increased risk of acquired immunodeficiency syndrome (A.I.D.S.). ..
  50. 2,5 CYCLOHEXADIENONES IN NATURAL PRODUCTS SYNTHESIS
    Mark Wentland; Fiscal Year: 2001
    ....